Medotilin solution for infection. 1000mg/4ml amp. 4 ml No. 3

Pharmacological properties

Pharmacodynamics. medotilin treats to group central holinomimetikiv with primary influence on central nervous system. sincaline alfostserat as the carrier of sincaline and the predecessor of phosphatidylsincaline has potential ability to prevent and korrigirovat the biochemical lesions which are of particular importance among pathogenic factors of a psychoorganic involutional syndrome that is can influence a reduced cholinergic tone and the changed phospholipidic structure of covers of neurons. 40.5% of metabolic protected sincaline are a part of drug. metabolic protection provides release of sincaline in a head brain. medotilin positively influences functions of memory and informative abilities and also indicators of an emotional state and behavior which deterioration is caused by development of involutional pathology of a brain.

on what at hit in a sincaline organism alfostserat is split under the influence of enzymes on sincaline and glycerophosphate: sincaline participates in biosynthesis of acetylcholine — one of the main mediators of nervous excitement; glycerophosphate is a predecessor of phospholipids (phosphatidylsincaline) of a neural membrane. Thus, Medotilin improves transfer of nervous impulses in cholinergic neurons, positively affects plasticity of neuronalny membranes and function of receptors. Medotilin improves a cerebral blood stream, strengthens metabolic processes in a head brain, activates structures of a reticular formation of a brain and restores consciousness at traumatic injury of a brain.

Pharmacokinetics. At Medotilin's introduction about 88% of the entered dose are on average absorbed. Drug collects mainly in a brain (45% of concentration of medicament in blood), lungs and a liver. Removal of medicament happens mainly through lungs in the form of carbon dioxide (85%), the residual quantity is distinguished with kidneys and through intestines.

Indication

Acute period of a severe craniocereberal injury with mainly stem level of damage (consciousness disturbance, coma, focal polusharny symptomatology, symptoms of damage of a brainstem). degenerative and involutional brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, that is primary and secondary disturbances of mental activity at elderly people who are characterized by memory disturbance, confusion of consciousness, a disorientation, decrease in motivation and initiative, decline in the ability to concentration; changes in the emotional sphere and sphere of behavior: emotional instability, irritability, indifference to the environment; pseudo-melancholy at elderly people.

Use

At acute conditions to administer the medicament in oil or in/in (slowly) on 1 g/days within from 15 to 20 days. after stabilization of a condition of the patient to pass to oral forms of drug.

Children. Experience of use for children is absent.

Contraindication

Known hypersensitivity to medicament components. psychotic syndrome, heavy psychomotor excitement. period of pregnancy and feeding by a breast.

Side effects

As a rule, medicament is well transferred even at long use. developing of nausea (which mainly is a consequence of secondary dopaminergic activation), decrease hell, a headache is possible; abdominal pain and short-term confusion of consciousness are very seldom possible. in that case it is necessary to lower a medicament dose. reactions in the injection site are possible. reactions of hypersensitivity, including rash, an itching, urticaria, a Quincke's disease, erubescence are possible.

Special instructions

Use during pregnancy or feeding by a breast. medicament is contraindicated for use during pregnancy or feeding by a breast.

Ability to influence speed of response at control of vehicles or other mechanisms. Drug does not influence control of vehicles and work with mechanisms.

Interaction

.

Overdose

in case of overdose note the nausea, concern, excitement, insomnia passing later dose declines or the terminations of treatment. symptomatic therapy.

to Store

at a temperature not above 25 °C in the dry, protected from light place